PART I . TNF is a clinical stage pharmaceutical company committed to extending healthy lifespan. TNF is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets, Isomyosamine and Supera-CBD: Isomyosamine is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including (but not limited to) sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, an...
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-11 | 2024-12-31 | 0001641172-25-003814 | EDGAR | 133K words |
| 2024-04-01 | 2023-12-31 | 0001493152-24-012533 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010384 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001493152-22-008546 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001493152-21-005129 | EDGAR | — |
| 2020-03-25 | 2019-12-31 | 0001493152-20-004650 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001493152-19-004590 | EDGAR | — |
| 2018-04-03 | 2017-12-31 | 0001493152-18-004626 | EDGAR | — |
| 2017-04-11 | 2016-12-31 | 0001493152-17-003722 | EDGAR | — |
| 2016-03-30 | 2015-12-31 | 0001493152-16-008364 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-19 | 2025-09-30 | 0001493152-25-024320 | EDGAR | 61K words |
| 2025-08-19 | 2025-06-30 | 0001641172-25-024859 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010937 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-046026 | EDGAR | — |
| 2024-08-19 | 2024-06-30 | 0001493152-24-032940 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019976 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001493152-23-041328 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001493152-23-028603 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001493152-23-017488 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001493152-22-031423 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022611 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001493152-22-013927 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-13 | 0001493152-26-010070 | EDGAR | 1K words |
| 2026-01-23 | 0001493152-26-003440 | EDGAR | — |
| 2025-12-09 | 0001493152-25-026798 | EDGAR | — |
| 2025-11-14 | 0001493152-25-023596 | EDGAR | — |
| 2025-10-03 | 0001493152-25-016927 | EDGAR | — |
| 2025-09-26 | 0001493152-25-015774 | EDGAR | — |
| 2025-09-10 | 0001641172-25-027052 | EDGAR | — |
| 2025-09-02 | 0001641172-25-026167 | EDGAR | — |
| 2025-06-06 | 0001641172-25-014103 | EDGAR | — |
| 2025-05-09 | 0001641172-25-009514 | EDGAR | — |
279 total filings indexed. 247 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001321834 |
| Ticker | QCLS |
| Exchange | Nasdaq |
| SIC | 2835: In Vitro & In Vivo Diagnostic Substances |
| Incorporated | DE |
| Website | https://www.qctechnologies.com |
| Listed | 2021-04-19 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report